These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 22672156)

  • 1. Escalating therapy of cutaneous side effects of EGFR inhibitors: experience of German reference centers.
    Homey B; Gerber PA; Wollenberg A; Dirschka T; Hassel JC; Bölke E; Hauschild A; Gutzmer R
    J Dtsch Dermatol Ges; 2012 Aug; 10(8):559-63. PubMed ID: 22672156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous side-effects of EGFR inhibitors and their management.
    Ehmann LM; Ruzicka T; Wollenberg A
    Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician.
    Gutzmer R; Becker JC; Enk A; Garbe C; Hauschild A; Leverkus M; Reimer G; Treudler R; Tsianakas A; Ulrich C; Wollenberg A; Homey B
    J Dtsch Dermatol Ges; 2011 Mar; 9(3):195-203. PubMed ID: 21059173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drug therapies and their effect on the skin.
    Treudler R
    J Dtsch Dermatol Ges; 2009 Jul; 7(7):623-37. PubMed ID: 19614812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General management strategy for epidermal growth factor receptor inhibitor-associated papulopustular eruption.
    Farahnik B; Kwong B; Murase J
    J Am Acad Dermatol; 2016 Nov; 75(5):e191. PubMed ID: 27745649
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of the cutaneous side effects of therapeutic epidermal growth factor receptor inhibition.
    Reck M; Gutzmer R
    Onkologie; 2010; 33(8-9):470-9. PubMed ID: 20838065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous reactions to epidermal growth factor receptor inhibitors.
    Pomerantz RG; Mirvish ED; Geskin LJ
    J Drugs Dermatol; 2010 Oct; 9(10):1229-34. PubMed ID: 20941947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manage skin toxicities associated with EGFR inhibitors.
    Becze E
    ONS Connect; 2008 Jun; 23(6):22-3. PubMed ID: 18572873
    [No Abstract]   [Full Text] [Related]  

  • 9. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum.
    Pérez-Soler R; Delord JP; Halpern A; Kelly K; Krueger J; Sureda BM; von Pawel J; Temel J; Siena S; Soulières D; Saltz L; Leyden J
    Oncologist; 2005 May; 10(5):345-56. PubMed ID: 15851793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toward evidence-based management of the dermatologic effects of EGFR inhibitors.
    LoRusso P
    Oncology (Williston Park); 2009 Feb; 23(2):186-94. PubMed ID: 19323301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
    Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
    Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticipating and managing the cutaneous side effects of epidermal growth factor receptor inhibitors.
    Sinclair R
    Asia Pac J Clin Oncol; 2014 Mar; 10 Suppl 1():11-7. PubMed ID: 24512509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical management of EGFRI dermatologic toxicities: US perspective.
    Lacouture ME; Cotliar J; Mitchell EP
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):17-21. PubMed ID: 18154214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
    Tan EH; Chan A
    Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical approaches to minimize rash associated with EGFR inhibitors.
    Oishi K
    Oncol Nurs Forum; 2008 Jan; 35(1):103-11. PubMed ID: 18192159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches.
    Nikolaou V; Stratigos A; Antoniou C; Kiagia M; Nikolaou C; Katsambas A; Syrigos K
    Dermatology; 2010; 220(3):243-8. PubMed ID: 20110632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective.
    Iacovelli L
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):31-3. PubMed ID: 18154216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of epidermal growth factor receptor antagonist-induced skin rash: results of a survey among German oncologists.
    Hassel JC; Kripp M; Al-Batran S; Hofheinz RD
    Onkologie; 2010; 33(3):94-8. PubMed ID: 20215799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical management of EGFRI dermatologic toxicities: the nursing perspective.
    Purdom M; Ohinata A
    Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):29-30. PubMed ID: 18154215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous drug eruptions associated with the use of new oncological drugs.
    Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
    Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.